Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context

Summary: Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.S COVID-19 vaccine with seasonal influenza vaccines. Methods: This non-inferiority, Phase 3, randomised, double-bli...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:EClinicalMedicine
Subjects:
SARS-CoV-2
COVID-19
Vaccine
Adenoviral vectors
Influenza vaccines
Co-administration
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024005959
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024005959

Similar Items